1. Home
  2. TNXP vs SMC Comparison

TNXP vs SMC Comparison

Compare TNXP & SMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • SMC
  • Stock Information
  • Founded
  • TNXP 2007
  • SMC 2009
  • Country
  • TNXP United States
  • SMC United States
  • Employees
  • TNXP N/A
  • SMC N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • SMC
  • Sector
  • TNXP Health Care
  • SMC
  • Exchange
  • TNXP Nasdaq
  • SMC NYSE
  • Market Cap
  • TNXP 272.0M
  • SMC 322.4M
  • IPO Year
  • TNXP N/A
  • SMC 2012
  • Fundamental
  • Price
  • TNXP $35.48
  • SMC $25.29
  • Analyst Decision
  • TNXP Strong Buy
  • SMC
  • Analyst Count
  • TNXP 2
  • SMC 0
  • Target Price
  • TNXP $585.00
  • SMC N/A
  • AVG Volume (30 Days)
  • TNXP 729.5K
  • SMC 161.4K
  • Earning Date
  • TNXP 08-15-2025
  • SMC 08-07-2025
  • Dividend Yield
  • TNXP N/A
  • SMC N/A
  • EPS Growth
  • TNXP N/A
  • SMC N/A
  • EPS
  • TNXP N/A
  • SMC N/A
  • Revenue
  • TNXP $10,041,000.00
  • SMC $444,383,000.00
  • Revenue This Year
  • TNXP $11.66
  • SMC N/A
  • Revenue Next Year
  • TNXP $793.18
  • SMC N/A
  • P/E Ratio
  • TNXP N/A
  • SMC N/A
  • Revenue Growth
  • TNXP N/A
  • SMC N/A
  • 52 Week Low
  • TNXP $6.76
  • SMC $23.53
  • 52 Week High
  • TNXP $130.00
  • SMC $45.89
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 52.96
  • SMC 46.24
  • Support Level
  • TNXP $33.71
  • SMC $23.53
  • Resistance Level
  • TNXP $38.13
  • SMC $26.13
  • Average True Range (ATR)
  • TNXP 2.62
  • SMC 0.96
  • MACD
  • TNXP -0.44
  • SMC 0.04
  • Stochastic Oscillator
  • TNXP 61.01
  • SMC 50.57

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About SMC SUMMIT MIDSTREAM CORPORATION

Summit Midstream Corp is a value-driven corporation focused on developing, owning and operating midstream energy infrastructure assets strategically located in unconventional resource basins, shale formations, in the continental U.S. It currently operates natural gas, crude oil and produced water gathering systems in four unconventional resource basins: the Williston Basin in North Dakota, which includes the Bakken and Three Forks shale formations; the Denver-Julesburg Basin, which includes the Niobrara and Codell shale formations in Colorado and Wyoming; the Fort Worth Basin in Texas, which includes the Barnett Shale formation; and the Piceance Basin in Colorado, which includes the liquids-rich Mesaverde formation as well as the emerging Mancos and Niobrara Shale formations.

Share on Social Networks: